
==== Front
Pharmaceuticals (Basel)
Pharmaceuticals (Basel)
pharmaceuticals
Pharmaceuticals
1424-8247
MDPI

33922620
10.3390/ph14050401
pharmaceuticals-14-00401
Review
Pharmacology, Physiology and Genetics of the Neuropeptide S System
Reinscheid Rainer K. 12*
https://orcid.org/0000-0003-1360-202X
Ruzza Chiara 3*
Carvalho Félix Academic Editor
1 Institute of Pharmacology & Toxicology, University Hospital Jena, Friedrich-Schiller University, 07747 Jena, Germany
2 Institute of Physiology I, University Hospital Münster, Westfälische-Wilhelms University, 48149 Münster, Germany
3 Department of Neuroscience and Rehabilitation and Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, 44121 Ferrara, Italy
* Correspondence: rainer.reinscheid@med.uni-jena.de (R.K.R.); rzzchr@unife.it (C.R.)
23 4 2021
5 2021
14 5 40115 3 2021
21 4 2021
© 2021 by the authors.
2021
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
The Neuropeptide S (NPS) system is a rather ‘young’ transmitter system that was discovered and functionally described less than 20 years ago. This review highlights the progress that has been made in elucidating its pharmacology, anatomical distribution, and functional involvement in a variety of physiological effects, including behavior and immune functions. Early on, genetic variations of the human NPS receptor (NPSR1) have attracted attention and we summarize current hypotheses of genetic linkage with disease and human behaviors. Finally, we review the therapeutic potential of future drugs modulating NPS signaling. This review serves as an introduction to the broad collection of original research papers and reviews from experts in the field that are presented in this Special Issue.

transmitter
GPCR
brainstem
anxiety
memory
genetic variation
==== Body
1. NPS and the Orphan Receptor Strategy

Neuropeptide S (NPS) was discovered as a ligand of a previously orphan G protein-coupled receptor (GPCR) by using the “orphan receptor strategy”, also known as “reverse pharmacology” [1]. The receptor (previously known as GPR154 or GPRA) was stably expressed in cells that served as a bait to purify the endogenous ligand from brain extracts [2]. The ligand turned out to be a peptide of 20 amino acids that contains a perfectly conserved serine (single amino acid code “S”) at the N-terminus in all species analyzed, and was thus termed accordingly [3]. NPS is encoded as a single copy peptide by a rather small precursor protein (<90 amino acids) that occurs in the genome of all tetrapods but is absent from fish [4]. The seven N-terminal residues are identical in all tetrapods, as well as the overall 20 amino acid length, while the C-terminal half shows more variation (Figure 1).

A shortened peptide has been identified in a cephalochordate that contains the conserved amino terminal residues [5]. Together with the identification of a distantly-related GPCR from the same class of animals, this suggests a rather complex evolution of the NPS system in bilaterians, where teleost fish may have lost both genes [6].

NPSR1 is also a single-copy gene with moderate similarity to other peptide GPCRs, the closest being vasopressin 1A and oxytocin receptors. NPSR1 is found in the genomes of all tetrapods and no convincing orthologues have been identified in fish genomes [7].

2. General Pharmacology

NPSR1 couples via Gαs and Gαq to elevate intracellular cAMP and Ca2+, thus it is an excitatory GPCR [8]. Activation of mitogen-activated protein kinase (MAPK) pathways and opening of neuronal Ca2+ channels have also been described [8,9,10]. NPS activates its receptor at low nanomolar concentrations and structure-activity relationship (SAR) studies have confirmed the importance of the amino terminus for agonist activity, overlapping with the high evolutionary conservation of this part of the peptide structure [11,12,13]. Focused SAR studies performed on Gly5 lead to the identification of peptidergic NPSR1 antagonists, characterized by a D-amino acid with a short branched aliphatic side chain [14,15]. Some well-characterized NPSR1 antagonists identified in the frame of these studies are [D-Cys(t-Bu)5]NPS, [D-Val5]NPS, and [t-Bu-D-Gly5]NPS [15,16,17].

The prototype synthetic NPSR1 antagonist is SHA 68, belonging to the class of diphenyltetrahydro-1H-oxazolo [3,4-α]pyrazines [18] (Figure 2). SHA 68, and the closely related SHA 66, display nanomolar affinity for NPSR1 in vitro but only limited bioavailability in vivo, due to its high lipophilicity. Using the core structure of SHA 68, several refinements have been made to improve in vivo potency. It appears that slight increases in polarity can indeed cause an increased in vivo potency, albeit with a net loss in receptor affinity [19,20,21,22]. Additional high-throughput drug screening programs have yielded further structures with NPSR1 antagonistic profiles (Figure 2), although with lower in vitro and in vivo potency compared to SHA 68 [23,24,25]. None of these compounds has progressed beyond the preclinical stage yet.

3. Anatomical Distribution of the NPS System

Expression of NPS precursor and receptor mRNA have been studied in detail in brain. In rats and mice, the NPS precursor mRNA is expressed in only a few brainstem nuclei, most notably the pericoerulear region and the lateral parabrachial area including the Kölliker–Fuse nucleus [3,26,27]. In rat brain, additional NPS expression is detected in the principal sensory trigeminal nucleus and a few scattered cells in hypothalamus and amygdala. Widespread co-localization with excitatory neurotransmitters—including glutamate, acetylcholine, CRF or galanin—in the brainstem nuclei supports the view that NPS is part of an excitatory signaling system. Notably, in rat or mouse locus coeruleus (LC) NPS is not colocalized with noradrenaline in the LC proper, but found in immediately adjacent neurons. Using transgenic NPS-EGFP mice, the total number of NPS-expressing neurons in the mouse brain was determined to be ~500 [28], which makes it one of the rarest neuropeptides in the brain. Immunohistochemical analyses, however, revealed widespread projections of NPS-immunopositive fibers throughout the mouse brain, with highest densities found in hypothalamus, thalamus, and structures of the extended amygdala [27,28]. It is currently unkown if these fiber projections also represent synaptic terminals, but a few studies have investigated in vivo NPS release in certain brain areas. For example, increased NPS release upon stress exposure has been detected in the rat amygdala by microdialysis, demonstrating that it is a functional neurotransmitter [29]. Regulation of NPS transcripts has been observed in rat brain after sleep deprivation [30] or treatment with neuroleptics [31,32].

NPSR1 mRNA expression is found in many areas of the rodent brain, with highest densities in several cortical structures, thalamic nuclei, hypothalamus, subiculum, and amygdala [3,26,27]. Neuroleptics and chronic morphine also appear to regulate NPSR1 mRNA in certain areas of the rat brain [31,32,33].

Expression of NPS precursor or receptor mRNA in peripheral tissues has not been studied by in-situ hybridization but bulk mRNA has been quantified from whole organs. In rats, precursor and receptor mRNA was detected by RT-PCR in endocrine tissues, including mammary and salivary glands as well as thyroid [3]. Endogenous expression of NPSR1 was also observed in neuroendocrine tumors [9] and established colon cancer cell lines [8].

Information about NPS expression in the human brain is limited as only the pons has been investigated in detail. Similar to rodents, clusters of NPS-expressing neurons were found in the human lateral parabrachial nucleus as well as the pericoerulear region, although with a different quantitative distribution pattern compared to rodents [34]. An additional cluster of NPS mRNA-positive neurons was identified in the pontine central gray matter in both human and rat brain. The overall estimate for the human pons predicts a number of ~22,000 NPS-producing neurons. NPSR1 expression was detected by in-situ hybridization in various human tegmental nuclei and the periaqueductal gray, however, a comprehensive brain map for human or primate NPSR1 has yet to be produced.

Anatomical studies using anti-NPSR1 antibodies have so far not been verified by using knockout controls to validate the specificity of the antisera [9,35,36,37,38]. Therefore, the precise subcellular location of the receptor proteins is currently unknown.

4. Physiological and Behavioral Effects of NPS

4.1. Modulation of Animal Behavior

In experimental animals, NPS was found to induce arousal and wakefulness [3,39], reduce fear and anxiety [3,39,40,41,42,43,44], promote learning and memory consolidation [45,46,47], accelerate fear extinction [48,49], attenuate pharmacologically-induced psychotic behaviors [50], stimulate release of stress hormones [51,52] and prefrontal dopamine [53], produce analgesia [54,55,56,57,58,59], attenuate food intake [51,60,61], counteract motor deficits in a model of Parkinson’s disease [62], and promote drug-seeking behaviors including relapse of drug seeking [63,64,65,66,67]. An overview about animal models, routes and location of drug administration, and behavioral paradigms can be found in the review by Ruzza et al. [25]. Importantly, NPS-dependent stimulation of, or relapse to, either alcohol or cocaine seeking behavior can be blocked by NPSR1 antagonists [67,68]. Hypothalamic NPSR1 appear to be critical for modulating drug seeking behaviors and may interact with orexin/hypocretin and corticotropin-releasing factor neurotransmission [63,69,70]. Notably, both central (intracerebroventricular) and intra-amygdala administration of NPS elicited acute anxiolytic-like effects [3,48], while intra-amygdala administration of SHA 68 produced increased anxiety-like behavior [48], suggesting endogenous NPS release upon stress exposure. It appears that NPS may have a unique bifurcated effect on anxiety: while acutely attenuating anxiety-like responses, it later appears to facilitate extinction of fear memories. This combination of activities could be desirable therapeutic effects in the treatment of generalized anxiety disorders, phobias, panic disorder, or post-traumatic stress disorder.

There is limited evidence for a role of NPS in mood regulation. In the high-anxiety Flinders rat model, NPS normalized anxiety-like behaviors without producing anti-depressant effects in the forced swim test [71]. However, localized NPS administrations into the nucleus accumbens (NAc) shell, but not the NAc core or the bed nucleus of the stria terminalis (BNST), were reported to induce anti-depressant effects in a learned helplessness model in rats [72]. Unexpectedly, infusions of the NPSR1 antagonist SHA 68 into the BNST, another important part of the extended amygdala network regulating mood and anxiety, also produced anti-depressant-like effects. However, knockout mouse models did not exhibit depression-like phenotypes. Further studies may be required to clarify possible functions of endogenous NPS in mood regulation.

Prominent phenotypes in knockout mouse models for NPSR1 and NPS include attenuated arousal, deficits in learning and memory including disrupted fear learning, and mildly increased anxiety [45,52,73,74,75]. While the anxiogenic and memory impairment phenotype of NPSR1 knockout mice has not been replicated in all laboratories [76], all studies showed that the stimulant, arousal-promoting, and anxiolytic effects of NPS completely disappeared in NPSR1 knockout animals, demonstrating that NPSR1 is the unique protein by which NPS exerts its biological actions [52,73,74,76].

No respiratory phenotypes were detected in NPSR1 knockout mice, including models of induced asthma [77]. However, central NPS administration can stimulate respiratory frequency in an NPSR1-dependent manner [78].

4.2. NPS and Immune Functions

A few in vitro studies have described effects of NPS on lymphocytes or macrophages [79,80,81]. In general, NPS was found to induce lymphocyte proliferation and promote macrophage phagocytosis. These effects were accompanied by upregulated expression of pro-inflammatory cytokines. Whether any immune-modulatory deficits exist in NPSR1 or NPS knockout mice has not yet been established. Increased expression of NPSR1 in eosinophils from patients with asthma or severe inflammation has been reported [82].

5. Genetics of the Human NPS System and Associations with Disease and Behavior

The region on human chromosome 7 harboring NPSR1 was first identified in a positional cloning approach to contain an asthma-susceptibility gene. NPSR1 was one of the candidate genes and was termed GPRA (G protein-coupled receptor for asthma susceptibility) [35]. Further studies have reported genetic linkage of the NPSR1 locus on human Chr7 with inflammatory or allergic disorders, including asthma, airway hyper-responsiveness, atopic dermatitis, inflammatory bowel syndrome, and rheumatoid arthritis [83,84,85,86,87,88,89,90,91,92,93,94], although some studies failed to replicate such associations [95,96,97,98]. Complex haplotypes in and surrounding the NPSR1 gene, rather than individual single nucleotide polymorphisms (SNPs), were identified in these association studies and a detailed physiological mechanism has not yet been described to explain NPSR1-related functions in allergic or inflammatory diseases. Furthermore, NPSR1 knockout mice did not display asthma-related phenotypes or deficits in respiratory functions [77]. Instead, a neurogenic mechanism involving brainstem NPSR1 has been suggested to regulate NPS-dependent respiratory effects in mice [78]. Despite strong human genetic data, the physiological role of NPSR1 in asthma, allergies, or inflammation remains unclear.

Phenotypes of a missense mutation in NPSR1 received considerable attention because the Ile107Asn variants (rs324981, T/A) display 5–10 fold differences in agonist potency while binding affinity is not affected [8,99]. The rs324981 SNP is human-specific and the derived A-allele produces NPSR1-Asn107 with significantly reduced receptor expression and attenuated functionality. The NPRS1-Asn107 variant is also part of several haplotypes that have been associated with allergic and inflammatory diseases and was postulated to provide some protective effect, despite not showing any significant association on its own.

Due to its pharmacological phenotype, rs324981 was studied most intensely in humans and has been associated with panic disorder, anxiety, fear evaluation, stress responsiveness, maladaptive personality traits, early-onset bipolar disorder, and sleep [100,101,102,103,104,105,106,107,108,109,110,111]. Paradoxically, the ancestral T-allele, coding for the high-sensitivity variant NPSR1-Ile107, was often associated with disease phenotypes, except for a schizophrenia study where T-carriers displayed improved cognitive performance [112]. Tests in healthy human volunteers revealed T-carrier-specific associations with over-interpretation of fear or fearful stimuli, and functional brain scans showed rs324981 allele-dependent changes in neuronal activity in discrete brain areas in controls vs. panic or anxiety disorder patients, in particular involving specific subdivisions of the prefrontal and orbitofrontal cortex [104,106,107,109,113].

Surprisingly, the derived A-allele of rs324981 (encoding the low-functionality variant NPSR1-Asn107) has become the major allele in European and Asian populations, suggesting some form of selection. Analysis of worldwide rs324981 allele frequencies suggests an African origin of the mutation before the onset of migrations by anatomically-modern humans, consistent with the out-of-Africa hypothesis [114].

Recently, a gain-of-function variant (NPSR1-His206) has been described in a single family that dramatically reduces total sleep time [115]. This observation confirms earlier genetic association reports of the high-activity variant NPSR1-Ile107 with delayed bedtime [101] and supports a significant role for NPS in arousal.

A mutation reducing agonist potency 10–20 fold has been identified in the NPS peptide itself, producing Leu6-NPS (instead of Val6; rs4751440, G/C) [94,116]. Thus far, no phenotypes have been associated with this variant, which might be due to the relatively low allele frequency and geographically restricted occurrence in European and Indian populations. Interestingly, genetic analysis showed that the rs4751440 mutation may have originated in Neandertals, since it is found in all currently available Neandertal genomes. Most likely, the mutant allele was introduced into the anatomically-modern human gene pool by interbreeding with Neandertals in Southern Europe after the main migrations to East Asia had already occurred [114].

6. Therapeutic Potential

The prospect of a non-sedative anxiolytic stimulated a lot of interest in the pharmaceutical industry to search for small-molecule NPSR1 agonists. However, so far, no such molecules have been discovered. In contrast, various independent structures of small-molecule NPSR1 antagonists have been described (Figure 2), but thus far none of them have entered clinical trials. Based on preclinical data, such compounds may have therapeutic potential as sleep medications or in the treatment of drug addiction, especially to prevent relapse of drug abuse [23,25,68,117].

7. Concluding Remarks

An impressive number of physiological functions have been identified for the NPS system in the relatively short time since its discovery. Together with the plethora of genetic association data for NPSR1 variants with human disease and behaviors, increased efforts to identify therapeutic applications for this interesting transmitter system appear to be promising and warranted. The articles in this Special Issue reflect the continuing progress in our knowledge about the NPS system and its therapeutic potential.

Author Contributions

Conceptualization, R.K.R., C.R.; writing—original draft preparation, R.K.R., C.R.; writing—review and editing, R.K.R., C.R.; All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data sharing not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Figure 1 Neuropeptide S (NPS) or NPS-like peptide sequences. Residues divergent from the human NPS sequence are highlighted in red. The C-terminal amide (NH2) in the Branchiostoma peptide is encoded by glycine in the precursor protein and therefore identical to the consensus.

Figure 2 Chemical structures of NPSR1 antagonists. Details about synthesis and pharmacological activities can be found in the original literature. SHA 68 [18], RTI-118 [68], PI1 [118], MLS001018695 [119], NCGC84 [23], QA1 [120], R06039-478 [121].

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Civelli O. Saito Y. Wang Z. Nothacker H.-P. Reinscheid R.K. Orphan GPCRs and their ligands Pharmacol. Ther. 2006 110 525 532 10.1016/j.pharmthera.2005.10.001 16289308
2. Sato S. Shintani Y. Miyajima N. Yoshimura K. Novel G protein-coupled receptor protein and DNA thereof World Patent WO 02/31145 A1 18 4 2002
3. Xu Y.-L. Reinscheid R.K. Huitron-Resendiz S. Clark S.D. Wang Z. Lin S.H. Brucher F.A. Zeng J. Ly N.K. Henriksen S.J. Neuropeptide S: A neuropeptide promoting arousal and anxiolytic-like effects Neuron 2004 43 487 497 10.1016/j.neuron.2004.08.005 15312648
4. Reinscheid R.K. Phylogenetic appearance of neuropeptide S precursor proteins in tetrapods Peptides 2007 28 830 837 10.1016/j.peptides.2007.01.008 17293003
5. Elphick M.R. NG peptides: A novel family of neurophysin-associated neuropeptides Gene 2010 458 20 26 10.1016/j.gene.2010.03.004 20303398
6. Mirabeau O. Joly J.S. Molecular evolution of peptidergic signaling systems in bilaterians Proc. Natl. Acad. Sci. USA 2013 110 E2028 E2037 10.1073/pnas.1219956110 23671109
7. Pitti T. Manoj N. Molecular evolution of the neuropeptide S receptor PLoS ONE 2012 7 e34046 10.1371/journal.pone.0034046 22479518
8. Reinscheid R.K. Xu Y.-L. Okamura N. Zeng J. Chung S. Pai R. Wang Z. Civelli O. Pharmacological characterization of human and murine neuropeptide S receptor variants J. Pharmacol. Exp. Ther. 2005 315 1338 1345 10.1124/jpet.105.093427 16144971
9. Pulkkinen V. Ezer S. Sundman L. Hagström J. Remes S. Söderhäll C. Dario G. Haglund C. Kere J. Arola J. Neuropeptide S receptor 1 (NPSR1) activates cancer-related pathways and is widely expressed in neuroendocrine tumors Virchows Arch. 2014 465 173 183 10.1007/s00428-014-1602-x 24915894
10. Erdmann F. Kügler S. Blaesse P. Lange M.D. Skryabin B.V. Pape H.C. Jüngling K. Neuronal expression of the human neuropeptide S receptor NPSR1 identifies NPS-induced calcium signaling pathways PLoS ONE 2015 10 e0117319 10.1371/journal.pone.0117319 25714705
11. Roth A.L. Marzola E. Rizzi A. Arduin M. Trapella C. Corti C. Vergura R. Martinelli P. Salvadori S. Regoli D. Structure-activity studies on neuropeptide S: Identification of the amino acid residues crucial for receptor activation J. Biol. Chem. 2006 281 20809 20816 10.1074/jbc.M601846200 16720571
12. Camarda V. Trapella C. Caló G. Guerrini R. Rizzi A. Ruzza C. Fiorini S. Marzola E. Reinscheid R.K. Regoli D. Synthesis and biological activity of human neuropeptide S analogues modified in position 2 J. Med. Chem. 2008 51 655 658 10.1021/jm701204n 18181564
13. Camarda V. Trapella C. Calo’ G. Guerrini R. Rizzi A. Ruzza C. Fiorini S. Marzola E. Reinscheid R.K. Regoli D. Structure-activity study at positions 3 and 4 of human neuropeptide S Bioorganic Med. Chem. 2008 16 8841 8845 10.1016/j.bmc.2008.08.073
14. Guerrini R. Camarda V. Trapella C. Calò G. Rizzi A. Ruzza C. Fiorini S. Marzola E. Reinscheid R.K. Regoli D. Synthesis and biological activity of human neuropeptide S analogues modified in position 5: Identification of potent and pure neuropeptide S receptor antagonists J. Med. Chem. 2009 52 524 529 10.1021/jm8012294 19113861
15. Guerrini R. Camarda V. Trapella C. Caló G. Rizzi A. Ruzza C. Fiorini S. Marzola E. Reinscheid R.K. Regoli D. Further studies at neuropeptide S position 5: Discovery of novel neuropeptide S receptor antagonists J. Med. Chem. 2009 52 4068 4071 10.1021/jm900604g 19473027
16. Ruzza C. Rizzi A. Camarda V. Pulga A. Marzola G. Filaferro M. Novi C. Ruggieri V. Marzola E. Vitale G. [tBu-D-Gly5]NPS, a pure and potent antagonist of the neuropeptide S receptor: In vitro and in vivo studies Peptides 2012 34 404 411 10.1016/j.peptides.2012.01.024 22342393
17. Camarda V. Rizzi A. Ruzza C. Zucchini S. Marzola G. Marzola E. Guerrini R. Salvadori S. Reinscheid R.K. Regoli D. In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys(tBu)5]neuropeptide S J. Pharmacol. Exp. Ther. 2009 328 549 555 10.1124/jpet.108.143867 18971372
18. Okamura N. Habay S.A. Zeng J. Chamberlin A.R. Reinscheid R.K. Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor J. Pharmacol. Exp. Ther. 2008 325 893 901 10.1124/jpet.107.135103 18337476
19. Ruzza C. Rizzi A. Trapella C. Pela’ M. Camarda V. Ruggieri V. Filaferro M. Cifani C. Reinscheid R.K. Vitale G. Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68 Peptides 2010 31 915 925 10.1016/j.peptides.2010.02.012 20172007
20. Trapella C. Pela M. Del Zoppo L. Calo G. Camarda V. Ruzza C. Cavazzini A. Costa V. Bertolasi V. Reinscheid R.K. Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9 R/S)-3-Oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic Acid 4-fluoro-benzylamide (SHA 68) J. Med. Chem. 2011 54 2738 2744 10.1021/jm200138r 21466221
21. Hassler C. Zhang Y. Gilmour B. Graf T. Fennell T. Snyder R. Deschamps J.R. Reinscheid R.K. Garau C. Runyon S.P. Identification of neuropeptide s antagonists: Structure-Activity relationship studies, x-ray crystallography, and in vivo evaluation ACS Chem. Neurosci. 2014 5 731 744 10.1021/cn500113c 24964000
22. Albanese V. Ruzza C. Marzola E. Bernadi T. Fabbri M. Fantinati A. Trapella C. Reinscheid R.K. Ferrari F. Sturaro C. Structure-Activity Relationship Studies on Oxazolo[3,4-a]pyrazine Derivatives Leading to the Discovery of a Novel Neuropeptide S Receptor Antagonist with Potent In Vivo Activity J. Med. Chem. 2021 10.1021/acs.jmedchem.0c02223
23. Thorsell A. Tapocik J.D. Liu K. Zook M. Bell L. Flanigan M. Patnaik S. Marugan J. Damadzic R. Dehdashti S.J. A novel brain penetrant NPS receptor antagonist, NCGC00185684, blocks alcohol-induced ERK-phosphorylation in the central amygdala and decreases operant alcohol self-administration in rats J. Neurosci. 2013 33 10132 10142 10.1523/JNEUROSCI.4742-12.2013 23761908
24. Batran R.Z. Dawood D.H. El-Seginy S.A. Maher T.J. Gugnani K.S. Rondon-Ortiz A.N. Coumarinyl pyranopyrimidines as new neuropeptide S receptor antagonists; design, synthesis, homology and molecular docking Bioorg. Chem. 2017 75 274 290 10.1016/j.bioorg.2017.09.017 29055857
25. Ruzza C. Calò G. Di Maro S. Pacifico S. Trapella C. Salvadori S. Preti D. Guerrini R. Neuropeptide S receptor ligands: A patent review (2005–2016) Expert Opin. Ther. Pat. 2017 27 347 362 10.1080/13543776.2017.1254195 27788040
26. Xu Y.-L. Gall C.M. Jackson V.R. Civelli O. Reinscheid R.K. Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S-expressing neurons in the rat brain J. Comp. Neurol. 2007 500 84 102 10.1002/cne.21159 17099900
27. Clark S.D. Duangdao D.M. Schulz S. Zhang L. Liu X. Xu Y.L. Reinscheid R.K. Anatomical characterization of the neuropeptide S system in the mouse brain by in situ hybridization and immunohistochemistry J. Comp. Neurol. 2011 519 1867 1893 10.1002/cne.22606 21452235
28. Liu X. Zeng J. Zhou A. Theodorsson E. Fahrenkrug J. Reinscheid R.K. Molecular fingerprint of neuropeptide s-producing neurons in the mouse brain J. Comp. Neurol. 2011 519 1847 1866 10.1002/cne.22603 21452230
29. Ebner K. Rjabokon A. Pape H.C. Singewald N. Increased in vivo release of neuropeptide S in the amygdala of freely moving rats after local depolarisation and emotional stress Amino Acids 2011 41 991 996 10.1007/s00726-011-1058-0 21861171
30. Adori C. Barde S. Vas S. Ebner K. Su J. Svensson C. Mathé A.A. Singewald N. Reinscheid R.R. Uhlén M. Exploring the role of neuropeptide S in the regulation of arousal: A functional anatomical study Brain Struct. Funct. 2016 221 3521 3546 10.1007/s00429-015-1117-5 26462664
31. Palasz A. Rojczyk E. Golyszny M. Filipczyk L. Worthington J.J. Wiaderkiewicz R. Long-term treatment with haloperidol affects neuropeptide S and NPSR mRNA levels in the rat brain Acta Neuropsychiatr. 2016 28 110 116 10.1017/neu.2015.56 26467816
32. Pałasz A. Rojczyk E. Neuroleptics Affect Neuropeptide S and NPSR mRNA Levels in the Rat Brain J. Mol. Neurosci. 2015 57 352 357 10.1007/s12031-015-0625-3 26227793
33. Ghazal P. Ciccocioppo R. Ubaldi M. Morphine dependence is associated with changes in neuropeptide S receptorexpression and function in rat brain Peptides 2013 46 6 12 10.1016/j.peptides.2013.05.001 23684726
34. Adori C. Barde S. Bogdanovic N. Uhlén M. Reinscheid R.K. Kovacs G.G. Hökfelt T. Neuropeptide S-and Neuropeptide S receptor-expressing neuron populations in the human pons Front. Neuroanat. 2015 9 e126 10.3389/fnana.2015.00126
35. Laitinen T. Polvi A. Rydman P. Vendelin J. Pulkkinen V. Salmikangas P. Mäkelä S. Rehn M. Pirskanen A. Rautanen A. Characterization of a Common Susceptibility Locus for Asthma-Related Traits Science 2004 304 300 304 10.1126/science.1090010 15073379
36. Vendelin J. Pulkkinen V. Rehn M. Pirskanen A. Räisänen-Sokolowski A. Laitinen A. Laitinen L.A. Kere J. Laitinen T. Characterization of GPRA, a novel G protein-coupled receptor related to asthma Am. J. Respir. Cell Mol. Biol. 2005 33 262 270 10.1165/rcmb.2004-0405OC 15947423
37. Sundman L. Saarialho-Kere U. Vendelin J. Lindfors K. Assadi G. Kaukinen K. Westerholm-Ormio M. Savilahti E. Mäki M. Alenius H. Neuropeptide S receptor 1 expression in the intestine and skin—Putative role in peptide hormone secretion Neurogastroenterol. Motil. 2010 22 79 87 10.1111/j.1365-2982.2009.01366.x 19614867
38. Leonard S.K. Ring R.H. Immunohistochemical localization of the neuropeptide S receptor in the rat central nervous system Neuroscience 2011 172 153 163 10.1016/j.neuroscience.2010.10.020 20950671
39. Rizzi A. Vergura R. Marzola G. Ruzza C. Guerrini R. Salvadori S. Regoli D. Calo G. Neuropeptide S is a stimulatory anxiolytic agent: A behavioural study in mice Br. J. Pharmacol. 2008 154 471 479 10.1038/bjp.2008.96 18376418
40. Leonard S.K. Dwyer J.M. Sukoff Rizzo S.J. Platt B. Logue S.F. Neal S.J. Malberg J.E. Beyer C.E. Schechter L.E. Rosenzweig-Lipson S. Pharmacology of neuropeptide S in mice: Therapeutic relevance to anxiety disorders Psychopharmacology 2008 197 601 611 10.1007/s00213-008-1080-4 18311561
41. Ionescu I.A. Dine J. Yen Y.C. Buell D.R. Herrmann L. Holsboer F. Eder M. Landgraf R. Schmidt U. Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons Neuropsychopharmacology 2012 37 1323 1337 10.1038/npp.2011.317 22278093
42. Dine J. Ionescu I.A. Avrabos C. Yen Y.C. Holsboer F. Landgraf R. Schmidt U. Eder M. Intranasally applied neuropeptide S shifts a high-anxiety electrophysiological endophenotype in the ventral hippocampus towards a “normal”-anxiety one PLoS ONE 2015 10 e0120272 10.1371/journal.pone.0120272 25830625
43. Slattery D.A. Naik R.R. Grund T. Yen Y.C. Sartori S.B. Füchsl A. Finger B.C. Elfving B. Nordemann U. Guerrini R. Selective breeding for high anxiety introduces a synonymous SNP that increases Neuropeptide S receptor activity J. Neurosci. 2015 35 4599 4613 10.1523/JNEUROSCI.4764-13.2015 25788677
44. Zoicas I. Menon R. Neumann I.D. Neuropeptide S reduces fear and avoidance of con-specifics induced by social fear conditioning and social defeat, respectively Neuropharmacology 2016 108 284 291 10.1016/j.neuropharm.2016.03.054 27044664
45. Okamura N. Garau C. Duangdao D.M. Clark S.D. Jüngling K. Pape H.-C. Reinscheid R.K. Neuropeptide S enhances memory during the consolidation phase and interacts with noradrenergic systems in the brain Neuropsychopharmacology 2011 36 744 752 10.1038/npp.2010.207 21150909
46. Lukas M. Neumann I.D. Nasal application of neuropeptide S reduces anxiety and prolongs memory in rats: Social versus non-social effects Neuropharmacology 2012 62 398 405 10.1016/j.neuropharm.2011.08.016 21871467
47. Han R.W. Zhang R.S. Xu H.J. Chang M. Peng Y.L. Wang R. Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or Aβ1-42 in mice novel object and object location recognition tasks Neuropharmacology 2013 70 261 267 10.1016/j.neuropharm.2013.02.002 23454528
48. Jüngling K. Seidenbecher T. Sosulina L. Lesting J. Sangha S. Clark S.D. Okamura N. Duangdao D.M. Xu Y.-L. Reinscheid R.K. Neuropeptide S-Mediated Control of Fear Expression and Extinction: Role of Intercalated GABAergic Neurons in the Amygdala Neuron 2008 59 298 310 10.1016/j.neuron.2008.07.002 18667157
49. Sartori S.B. Maurer V. Murphy C. Schmuckermair C. Muigg P. Neumann I.D. Whittle N. Singewald N. Combined neuropeptide S and D-cycloserine augmentation prevents the return of fear in extinction-impaired rodents: Advantage of dual versus single drug approaches Int. J. Neuropsychopharmacol. 2016 19 1 11 10.1093/ijnp/pyv128
50. Okamura N. Reinscheid R.K. Ohgake S. Iyo M. Hashimoto K. Neuropeptide S attenuates neuropathological, neurochemical and behavioral changes induced by the NMDA receptor antagonist MK-801 Neuropharmacology 2010 58 166 172 10.1016/j.neuropharm.2009.06.027 19576911
51. Smith K.L. Patterson M. Dhillo W.S. Patel S.R. Semjonous N.M. Gardiner J.V. Ghatei M.A. Bloom S.R. Neuropeptide S stimulates the hypothalamo-pituitary-adrenal axis and inhibits food intake Endocrinology 2006 147 3510 3518 10.1210/en.2005-1280 16574794
52. Zhu H. Mingler M.K. McBride M.L. Murphy A.J. Valenzuela D.M. Yancopoulos G.D. Williams M.T. Vorhees C.V. Rothenberg M.E. Abnormal response to stress and impaired NPS-induced hyperlocomotion, anxiolytic effect and corticosterone increase in mice lacking NPSR1 Psychoneuroendocrinology 2010 35 1119 1132 10.1016/j.psyneuen.2010.01.012 20171785
53. Si W. Aluisio L. Okamura N. Clark S.D. Fraser I. Sutton S.W. Bonaventure P. Reinscheid R.K. Neuropeptide S stimulates dopaminergic neurotransmission in the medial prefrontal cortex J. Neurochem. 2010 115 475 482 10.1111/j.1471-4159.2010.06947.x 20722970
54. Li W. Chang M. Peng Y.L. Gao Y.H. Zhang J.N. Han R.W. Wang R. Neuropeptide S produces antinociceptive effects at the supraspinal level in mice Regul. Pept. 2009 156 90 95 10.1016/j.regpep.2009.03.013 19345242
55. Peng Y.L. Zhang J.N. Chang M. Li W. Han R.W. Wang R. Effects of central neuropeptide S in the mouse formalin test Peptides 2010 31 1878 1883 10.1016/j.peptides.2010.06.027 20603169
56. Victor Holanda A.D. Asth L. Santos A.R. Guerrini R. Soares-Rachetti V.D.P. Calo’ G. André E. Gavioli E.C. Central adenosine A1 and A2A receptors mediate the antinociceptive effects of neuropeptide S in the mouse formalin test Life Sci. 2015 120 8 12 10.1016/j.lfs.2014.10.021 25447449
57. Holanda V.A.D. Oliveira M.C. Souza L.S. Lobão-Soares B. André E. Da Silva Junior E.D. Guerrini R. Calo G. Ruzza C. Gavioli E.C. Dopamine D1 and D2 receptors mediate neuropeptide S-induced antinociception in the mouse formalin test Eur. J. Pharmacol. 2019 859 172557 10.1016/j.ejphar.2019.172557 31326375
58. Lee M.T. Chiu Y.T. Chiu Y.C. Hor C.C. Lee H.J. Guerrini R. Calo G. Chiou L.C. Neuropeptide S-initiated sequential cascade mediated by OX1, NK1, mGlu5 and CB1 receptors: A pivotal role in stress-induced analgesia J. Biomed. Sci. 2020 27 7 10.1186/s12929-019-0590-1 31915019
59. Jinushi K. Kushikata T. Kudo T. Calo G. Guerrini R. Hirota K. Central noradrenergic activity affects analgesic effect of Neuropeptide S J. Anesth. 2018 32 48 53 10.1007/s00540-017-2427-y 29128909
60. Peng Y.L. Han R.W. Chang M. Zhang L. Zhang R.S. Li W. Han Y.F. Wang R. Central Neuropeptide S inhibits food intake in mice through activation of Neuropeptide S receptor Peptides 2010 31 2259 2263 10.1016/j.peptides.2010.08.015 20800637
61. Cifani C. Di Bonaventura M.V.M. Cannella N. Fedeli A. Guerrini R. Calo G. Ciccocioppo R. Ubaldi M. Effect of neuropeptide S receptor antagonists and partial agonists on palatable food consumption in the rat Peptides 2011 32 44 50 10.1016/j.peptides.2010.10.018 20971145
62. Didonet J.J. Cavalcante J.C. Souza L.D. Costa M.S. André E. Soares-Rachetti V.D. Guerrini R. Gavioli E.C. Neuropeptide S counteracts 6-OHDA-induced motor deficits in mice Behav. Brain Res. 2014 266 29 36 10.1016/j.bbr.2014.03.002 24613977
63. Cannella N. Economidou D. Kallupi M. Stopponi S. Heilig M. Massi M. Ciccocioppo R. Persistent Increase of Alcohol-Seeking Evoked by Neuropeptide S: An Effect Mediated by the Hypothalamic Hypocretin System Neuropsychopharmacology 2009 34 2125 2134 10.1038/npp.2009.37 19322167
64. Cannella N. Kallupi M. Li H.W. Stopponi S. Cifani C. Ciccocioppo R. Ubaldi M. Neuropeptide S differently modulates alcohol-related behaviors in alcohol-preferring and non-preferring rats Psychopharmacology 2016 233 2915 2924 10.1007/s00213-016-4333-7 27235017
65. Pañeda C. Huitron-Resendiz S. Frago L.M. Chowen J.A. Picetti R. De Lecea L. Roberts A.J. Neuropeptide S reinstates cocaine-seeking behavior and increases locomotor activity through corticotropin-releasing factor receptor 1 in mice J. Neurosci. 2009 29 4155 4161 10.1523/JNEUROSCI.5256-08.2009 19339610
66. Kallupi M. Cannella N. Economidou D. Ubaldi M. Ruggeri B. Weiss F. Massi M. Marugan J. Heilig M. Bonnavion P. Neuropeptide S facilitates cue-induced relapse to cocaine seeking through activation of the hypothalamic hypocretin system Proc. Natl. Acad. Sci. USA 2010 107 19567 19572 10.1073/pnas.1004100107 20974945
67. Kallupi M. De Guglielmo G. Cannella N. Li H.W. Caló G. Guerrini R. Ubaldi M. Renger J.J. Uebele V.N. Ciccocioppo R. Hypothalamic Neuropeptide S receptor blockade decreases discriminative cue-induced reinstatement of cocaine seeking in the rat Psychopharmacology 2013 226 347 355 10.1007/s00213-012-2910-y 23149909
68. Schmoutz C.D. Zhang Y. Runyon S.P. Goeders N.E. Antagonism of the neuropeptide S receptor with RTI-118 decreases cocaine self-administration and cocaine-seeking behavior in rats Pharmacol. Biochem. Behav. 2012 103 332 337 10.1016/j.pbb.2012.09.003 22982682
69. Cannella N. Kallupi M. Ruggeri B. Ciccocioppo R. Ubaldi M. The role of the neuropeptide S system in addiction: Focus on its interaction with the CRF and hypocretin/orexin neurotransmission Prog. Neurobiol. 2013 100 48 59 10.1016/j.pneurobio.2012.09.005 23041581
70. Ubaldi M. Giordano A. Severi I. Li H. Kallupi M. De Guglielmo G. Ruggeri B. Stopponi S. Ciccocioppo R. Cannella N. Activation of hypocretin-1/orexin-a neurons projecting to the bed nucleus of the stria terminalis and paraventricular nucleus is critical for reinstatement of alcohol seeking by neuropeptide S Biol. Psychiatry 2016 79 452 462 10.1016/j.biopsych.2015.04.021 26055195
71. Wegener G. Finger B.C. Elfving B. Keller K. Liebenberg N. Fischer C.W. Singewald N. Slattery D.A. Neumann I.D. Mathé A.A. Neuropeptide S alters anxiety, but not depression-like behaviour in Flinders Sensitive Line rats: A genetic animal model of depression Int. J. Neuropsychopharmacol. 2012 15 375 387 10.1017/S1461145711000678 21708052
72. Shirayama Y. Ishima T. Oda Y. Okamura N. Iyo M. Hashimoto K. Opposite roles for neuropeptide S in the nucleus accumbens and bed nucleus of the stria terminalis in learned helplessness rats Behav. Brain Res. 2015 291 67 71 10.1016/j.bbr.2015.05.007 25986404
73. Duangdao D.M. Clark S.D. Okamura N. Reinscheid R.K. Behavioral phenotyping of Neuropeptide S receptor knockout mice Behav. Brain Res. 2009 205 1 9 10.1016/j.bbr.2009.07.024 19646487
74. Fendt M. Buchi M. Bürki H. Imobersteg S. Ricoux B. Suply T. Sailer A.W. Neuropeptide S receptor deficiency modulates spontaneous locomotor activity and the acoustic startle response Behav. Brain Res. 2011 217 1 9 10.1016/j.bbr.2010.09.022 20888368
75. Liu X. Si W. Garau C. Jüngling K. Pape H.-C. Schulz S. Reinscheid R.K. Neuropeptide S precursor knockout mice display memory and arousal deficits Eur. J. Neurosci. 2017 46 1689 1700 10.1111/ejn.13613 28548278
76. Ruzza C. Pulga A. Rizzi A. Marzola G. Guerrini R. Calo’ G. Behavioural phenotypic characterization of CD-1 mice lacking the neuropeptide S receptor Neuropharmacology 2012 62 1999 2009 10.1016/j.neuropharm.2011.12.036 22248636
77. Allen I.C. Pace A.J. Jania L.A. Ledford J.G. Latour A.M. Snouwaert J.N. Bernier V. Stocco R. Therien A.G. Koller B.H. Expression and function of NPSR1/GPRA in the lung before and after induction of asthma-like disease Am. J. Physiol. Lung Cell. Mol. Physiol. 2006 291 L1005 L1017 10.1152/ajplung.00174.2006 16829631
78. Zhu H. Perkins C. Mingler M.K. Finkelman F.D. Rothenberg M.E. The role of neuropeptide S and neuropeptide S receptor 1 in regulation of respiratory function in mice Peptides 2011 32 818 825 10.1016/j.peptides.2010.12.002 21167892
79. Pulkkinen V. Majuri M.L. Wang G. Holopainen P. Obase Y. Vendelin J. Wolff H. Rytilä P. Laitinen L.A. Haahtela T. Neuropeptide S and G protein-coupled receptor 154 modulate macrophage immune responses Hum. Mol. Genet. 2006 15 1667 1679 10.1093/hmg/ddl090 16600990
80. Yao Y. Su J. Yang G. Zhang G. Lei Z. Zhang F. Li X. Kou R. Liu Y. Liu J. Effects of neuropeptide S on the proliferation of splenic lymphocytes, phagocytosis, and proinflammatory cytokine production of pulmonary alveolar macrophages in the pig Peptides 2011 32 118 124 10.1016/j.peptides.2010.09.021 20933561
81. Yao Y. Su J. Zhang F. Lei Z. Effects of central and peripheral administration of neuropeptide S on the level of serum proinflammatory cytokines in pigs Neuroimmunomodulation 2014 21 45 51 10.1159/000355977 24216974
82. Ilmarinen P. James A. Moilanen E. Pulkkinen V. Daham K. Saarelainen S. Laitinen T. Dahlén S.E. Kere J. Dahlén B. Enhanced expression of neuropeptide S (NPS) receptor in eosinophils from severe asthmatics and subjects with total IgE above 100 IU/ml Peptides 2014 51 100 109 10.1016/j.peptides.2013.10.030 24239856
83. Melén E. Bruce S. Doekes G. Kabesch M. Laitinen T. Lauener R. Lindgren C.M. Riedler J. Scheynius A. Van Hage-Hamsten M. Haplotypes of G protein-coupled receptor 154 are associated with childhood allergy and asthma Am. J. Respir. Crit. Care Med. 2005 171 1089 1095 10.1164/rccm.200410-1317OC 15710598
84. Kormann M.S.D. Carr D. Klopp N. Illig T. Leupold W. Fritzsch C. Weiland S.K. Von Mutius E. Kabesch M. G-Protein-coupled receptor polymorphisms are associated with asthma in a large German population Am. J. Respir. Crit. Care Med. 2005 171 1358 1362 10.1164/rccm.200410-1312OC 15764725
85. Hersh C.P. Raby B.A. Soto-Quirós M.E. Murphy A.J. Avila L. Lasky-Su J. Sylvia J.S. Klanderman B.J. Lange C. Weiss S.T. Comprehensive testing of positionally cloned asthma genes in two populations Am. J. Respir. Crit. Care Med. 2007 176 849 857 10.1164/rccm.200704-592OC 17702965
86. Bruce S. Nyberg F. Melén E. James A. Pulkkinen V. Orsmark-Pietras C. Bergström A. Dahlén B. Wickman M. Von Mutius E. The protective effect of farm animal exposure on childhood allergy is modified by NPSR1 polymorphisms J. Med. Genet. 2009 46 159 167 10.1136/jmg.2007.055137 18285428
87. Pulkkinen V. Haataja R. Hannelius U. Helve O. Pitkänen O.M. Karikoski R. Rehn M. Marttila R. Lindgren C.M. Hästbacka J. G protein-coupled receptor for asthma susceptibility associates with respiratory distress syndrome Ann. Med. 2006 38 357 366 10.1080/07853890600756453 16938805
88. Malerba G. Lindgren C.M. Xumerle L. Kiviluoma P. Trabetti E. Laitinen T. Galavotti R. Pescollderungg L. Boner A.L. Kere J. Chromosome 7p linkage and GPR154 gene association in Italian families with allergic asthma Clin. Exp. Allergy 2007 37 83 89 10.1111/j.1365-2222.2006.02615.x 17210045
89. D’Amato M. Zucchelli M. Seddighzadeh M. Anedda F. Lindblad S. Kere J. Alfredsson L. Klareskog L. Padyukov L. Analysis of neuropeptide S receptor gene (NPSR1) polymorphism in rheumatoid arthritis PLoS ONE 2010 5 e9315 10.1371/journal.pone.0009315 20179762
90. Vergara C. Jiménez S. Acevedo N. Martínez B. Mercado D. Gusmão L. Rafaels N. Hand T. Barnes K.C. Caraballo L. Association of G-protein-coupled receptor 154 with asthma and total IgE in a population of the Caribbean coast of Colombia Clin. Exp. Allergy 2009 39 1558 1568 10.1111/j.1365-2222.2009.03311.x 19624525
91. D’Amato M. Bruce S. Bresso F. Zucchelli M. Ezer S. Pulkkinen V. Lindgren C. Astegiano M. Rizzetto M. Gionchetti P. Neuropeptide S Receptor 1 Gene Polymorphism Is Associated With Susceptibility to Inflammatory Bowel Disease Gastroenterology 2007 133 808 817 10.1053/j.gastro.2007.06.012 17854592
92. Castro-Giner F. De Cid R. Gonzalez J.R. Jarvis D. Heinrich J. Janson C. Omenaas E.R. Matheson M.C. Pin I. Antó J.M. Positionally cloned genes and age-specific effects in asthma and atopy: An international population-based cohort study (ECRHS) Thorax 2010 65 124 131 10.1136/thx.2009.119628 19996348
93. Robledo G. González-Gay M.A. Fernández-Gutiérrez B. Lamas J.R. Balsa A. Pascual-Salcedo D. Castañeda S. Blanco R. González-Alvaro I. García A. NPSR1 gene is associated with reduced risk of rheumatoid arthritis J. Rheumatol. 2012 39 1166 1170 10.3899/jrheum.111205 22548958
94. Acevedo N. Ezer S. Merid S.K. Gaertner V.D. Söderhäll C. D’Amato M. Kabesch M. Melén E. Kere J. Pulkkinen V. Neuropeptide S (NPS) variants modify the signaling and risk effects of NPS Receptor 1 (NPSR1) variants in asthma PLoS ONE 2017 12 e0176568 10.1371/journal.pone.0176568 28463995
95. Shin H.D. Park K.S. Park C.S. Lack of association of GPRA (G protein-coupled receptor for asthma susceptibility) haplotypes with high serum IgE or asthma in a Korean population J. Allergy Clin. Immunol. 2004 114 1226 1227 10.1016/j.jaci.2004.08.003 15536436
96. Veal C.D. Reynolds N.J. Meggitt S.J. Allen M.H. Lindgren C.M. Kere J. Trembath R.C. Barker J.N. Absence of association between asthma and high serum immunoglobulin E associated GPRA haplotypes and adult atopic dermatitis J. Investig. Dermatol. 2005 125 399 401 10.1111/j.0022-202X.2005.23828.x 16098057
97. Wu H. Romieu I. Sienra-Monge J.J. del Rio-Navarro B.E. Burdett L. Yuenger J. Li H. Chanock S.J. London S.J. Lack of association between genetic variation in G-protein-coupled receptor for asthma susceptibility and childhood asthma and atopy Genes Immun. 2008 9 224 230 10.1038/gene.2008.8 18340359
98. Blakey J.D. Sayers I. Ring S.M. Strachan D.P. Hall I.P. Positionally cloned asthma susceptibility gene polymorphisms and disease risk in the British 1958 Birth Cohort Thorax 2009 64 381 387 10.1136/thx.2008.102053 19237393
99. Bernier V. Stocco R. Bogusky M.J. Joyce J.G. Parachoniak C. Grenier K. Arget M. Mathieu M.C. O’Neill G.P. Slipetz D. Structure-function relationships in the neuropeptide S receptor: Molecular consequences of the asthma-associated mutation N107I J. Biol. Chem. 2006 281 24704 24712 10.1074/jbc.M603691200 16790440
100. Okamura N. Hashimoto K. Iyo M. Shimizu E. Dempfle A. Friedel S. Reinscheid R.K. Gender-specific association of a functional coding polymorphism in the Neuropeptide S receptor gene with panic disorder but not with schizophrenia or attention-deficit/hyperactivity disorder Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007 31 1444 1448 10.1016/j.pnpbp.2007.06.026 17669576
101. Gottlieb D.J. O’Connor G.T. Wilk J.B. Genome-wide association of sleep and circadian phenotypes BMC Med. Genet. 2007 8 Suppl. 1 S9 10.1186/1471-2350-8-S1-S9 17903308
102. Laas K. Eensoo D. Paaver M. Lesch K.P. Reif A. Harro J. Further evidence for the association of the NPSR1 gene A/T polymorphism (Asn107Ile) with impulsivity and hyperactivity J. Psychopharmacol. 2015 29 878 883 10.1177/0269881115573803 25744621
103. Laas K. Reif A. Kiive E. Domschke K. Lesch K.P. Veidebaum T. Harro J. A functional NPSR1 gene variant and environment shape personality and impulsive action: A longitudinal study J. Psychopharmacol. 2014 28 227 236 10.1177/0269881112472562 23325374
104. Raczka K.A. Gartmann N. Mechias M.L. Reif A. Büchel C. Deckert J. Kalisch R. A neuropeptide S receptor variant associated with overinterpretation of fear reactions: A potential neurogenetic basis for catastrophizing Mol. Psychiatry 2010 15 1067 1074 10.1038/mp.2010.79 20628342
105. Donner J. Haapakoski R. Ezer S. Meln E. Pirkola S. Gratacs M. Zucchelli M. Anedda F. Johansson L.E. Sderhll C. Assessment of the neuropeptide S system in anxiety disorders Biol. Psychiatry 2010 68 474 483 10.1016/j.biopsych.2010.05.039 20705147
106. Domschke K. Reif A. Weber H. Richter J. Hohoff C. Ohrmann P. Pedersen A. Bauer J. Suslow T. Kugel H. Neuropeptide S receptor gene converging evidence for a role in panic disorder Mol. Psychiatry 2011 16 938 948 10.1038/mp.2010.81 20603625
107. Dannlowski U. Kugel H. Franke F. Stuhrmann A. Hohoff C. Zwanzger P. Lenzen T. Grotegerd D. Suslow T. Arolt V. Neuropeptide-S (NPS) receptor genotype modulates basolateral amygdala responsiveness to aversive stimuli Neuropsychopharmacology 2011 36 1879 1885 10.1038/npp.2011.73 21525857
108. Glotzbach-Schoon E. Andreatta M. Reif A. Ewald H. Tröger C. Baumann C. Deckert J. Mühlberger A. Pauli P. Contextual fear conditioning in virtual reality is affected by 5httlpr and npsr1 polymorphisms: Effects on fear-potentiated startle Front. Behav. Neurosci. 2013 7 31 10.3389/fnbeh.2013.00031 23630477
109. Tupak S.V. Reif A. Pauli P. Dresler T. Herrmann M.J. Domschke K. Jochum C. Haas E. Baumann C. Weber H. Neuropeptide S receptor gene: Fear-specific modulations of prefrontal activation Neuroimage 2013 66 353 360 10.1016/j.neuroimage.2012.10.033 23103692
110. Klauke B. Deckert J. Zwanzger P. Baumann C. Arolt V. Pauli P. Reif A. Domschke K. Neuropeptide S receptor gene (NPSR) and life events: G × e effects on anxiety sensitivity and its subdimensions World J. Biol. Psychiatry 2014 15 17 25 10.3109/15622975.2011.646302 22404660
111. Laas K. Reif A. Akkermann K. Kiive E. Domschke K. Lesch K.P. Veidebaum T. Harro J. Interaction of the neuropeptide S receptor gene Asn107Ile variant and environment: Contribution to affective and anxiety disorders, and suicidal behaviour Int. J. Neuropsychopharmacol. 2014 17 541 552 10.1017/S1461145713001478 24331455
112. Lennertz L. Quednow B.B. Schuhmacher A. Petrovsky N. Frommann I. Schulze-Rauschenbach S. Landsberg M.W. Steinbrecher A. Höfels S. Pukrop R. The functional coding variant Asn107Ile of the neuropeptide S receptor gene (NPSR1) is associated with schizophrenia and modulates verbal memory and the acoustic startle response Int. J. Neuropsychopharmacol. 2012 15 1205 1215 10.1017/S1461145711001623 22078257
113. Gechter J. Liebscher C. Geiger M.J. Wittmann A. Schlagenhauf F. Lueken U. Wittchen H.U. Pfleiderer B. Arolt V. Kircher T. Association of NPSR1 gene variation and neural activity in patients with panic disorder and agoraphobia and healthy controls NeuroImage Clin. 2019 24 102029 10.1016/j.nicl.2019.102029 31734525
114. Reinscheid R.K. Mafessoni F. Lüttjohann A. Jüngling K. Pape H.-C. Schulz S. Neandertal introgression and accumulation of hypomorphic mutations in the neuropeptide S (NPS) system promote attenuated functionality Peptides 2021 138 170506 10.1016/j.peptides.2021.170506 33556445
115. Xing L. Shi G. Mostovoy Y. Gentry N.W. Fan Z. McMahon T.B. Kwok P.Y. Jones C.R. Ptáček L.J. Fu Y.H. Mutant neuropeptide S receptor reduces sleep duration with preserved memory consolidation Sci. Transl. Med. 2019 11 eaax2014 10.1126/scitranslmed.aax2014 31619542
116. Deng C. He X. Hsueh A.J.W. A single-nucleotide polymorphism of human neuropeptide S gene originated from Europe shows decreased bioactivity PLoS ONE 2013 8 e83009 10.1371/journal.pone.0083009 24386135
117. Bonano J.S. Runyon S.P. Hassler C. Glennon R.A. Stevens Negus S. Effects of the neuropeptide S receptor antagonist RTI-118 on abuse-related facilitation of intracranial self-stimulation produced by cocaine and methylenedioxypyrovalerone (MDPV) in rats Eur. J. Pharmacol. 2014 743 98 105 10.1016/j.ejphar.2014.09.006 25220242
118. Trotter B.W. Nanda K.K. Manley P.J. Uebele V.N. Condra C.L. Gotter A.L. Menzel K. Henault M. Stocco R. Renger J.J. Tricyclic imidazole antagonists of the Neuropeptide S Receptor Bioorganic Med. Chem. Lett. 2010 20 4704 4708 10.1016/j.bmcl.2010.04.016
119. Patnaik S. Marugan J.J. Liu K. Zheng W. Southall N. Dehdashti S.J. Thorsell A. Heilig M. Bell L. Zook M. Structure-activity relationship of imidazopyridinium analogues as antagonists of neuropeptide s receptor J. Med. Chem. 2013 56 9045 9056 10.1021/jm400904m 24171469
120. Melamed J.Y. Zartman A.E. Kett N.R. Gotter A.L. Uebele V.N. Reiss D.R. Condra C.L. Fandozzi C. Lubbers L.S. Rowe B.A. Synthesis and evaluation of a new series of Neuropeptide S receptor antagonists Bioorganic Med. Chem. Lett. 2010 20 4700 4703 10.1016/j.bmcl.2010.04.143
121. Runyon S. Zhang Y. Hassler C. Gilmour B. Composition and method for Neuropeptide S receptor (NPSR) antagonists World Patent WO/2013/086200 13 6 2013

